LRP5L (Y-12): sc-86715



The Power to Question

BACKGROUND

Members of the LDL receptor gene family, including LDLR (low density lipoprotein receptor), LRPs (low density lipoprotein related proteins), megalin (also designated GP330), VLDLR (very low density lipoprotein receptor) and ApoER2, are characterized by a cluster of cysteine-rich class A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats and an O-linked sugar domain. Of the known family members, LRP5 is most closely related to LRP1. However, LRP5 has a unique organization of EGF and LDLR repeats compared to other LDLR family members and likely represents a new category in this family. LRP is expressed in rat tibia, specifically in areas of the bone that are involved in remodeling. LRP5 is a Wnt coreceptor that binds to Axin and regulates the canonical Wnt signaling pathway. LRP5 affects bone mass accrual during growth. Mutations in LRP5 cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome (OPPG). LRP5L is a related protein that exists as two isoforms produced by alternative splicing.

REFERENCES

- Hey, P.J., Twells, R.C., Phillips, M.S., Nakagawa, Y., Brown, S.D., Kawaguchi, Y., Cox, R., Xie, G., Dugan, V., Hammond, H., Metzker, M.L., Todd, J.A. and Hess, J.F. 1998. Cloning of a novel member of the low-density lipoprotein receptor family. Gene 216: 103-111.
- 2. Trommsdorff, M., Gotthardt, M., Hiesberger, T., Shelton, J., Stockinger, W., Nimpf, J., Hammer, R.E., Richardson, J.A., and Herz, J. 1999. Reeler/ Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL Receptor and ApoE Receptor 2. Cell 97: 689-701.
- Mikhailenko, I., Considine, W., Argraves, K.M., Loukinov, D., Hyman, B.T. and Strickland, D.K. 1999. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms. J. Cell Sci. 112: 3269-3281.
- Chen, D., Lathrop, W. and Dong, Y. 1999. Molecular cloning of mouse Lrp7 (Lr3) cDNA and chromosomal mapping of orthologous genes in mouse and human. Genomics 55: 314-321.
- Mao, J., Wang, J., Liu, B., Pan, W., Farr, G.H. III, Flynn, C., Yuan, H., Takada, S., Kimelman, D., Li, L. and Wu, D. 2001. Low-density lipoprotein receptorrelated protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7: 801-809.
- Gong, Y., Slee, R.B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A.M., Wang, H., Cundy, T., Glorieux, F.H., Lev, D., Zacharin, M., Oexle, K., Marcelino, J., Suwairi, W., Heeger, S., Sabatakos, G., Apte, S., Adkins, W.N., et. al. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
- 7. Little, R.D., Carulli, J.P., Del Mastro, R.G., Dupuis, J., Osborne, M., Folz, C., Manning, S.P., Swain, P.M., Zhao, S.C., Eustace, B., Lappe, M.M., Spitzer, L., Zweier, S., Braunschweiger, K., Benchekroun, Y., Hu, X., Adair, R., Chee, L., FitzGerald, M.G., Tulig, C., Caruso, A., Tzellas, N., Bawa, A., Franklin, B., McGuire, S., Nogues, X., Gong, G., Allen, K.M., Anisowicz, A., Morales, A.J., Lomedico, P.T., Recker, S.M., Van Eerdewegh, P., Recker, R.R. and Johnson, M.L. 2002. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70: 11-19.

CHROMOSOMAL LOCATION

Genetic locus: LRP5L (human) mapping to 22q11.23.

SOURCE

LRP5L (Y-12) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of LRP5L of human origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-86715 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

LRP5L (Y-12) is recommended for detection of LRP5L of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for LRP5L siRNA (h): sc-75697, LRP5L shRNA Plasmid (h): sc-75697-SH and LRP5L shRNA (h) Lentiviral Particles: sc-75697-V.

Molecular Weight of LRP5L isoforms: 28/26 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com